Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

New research suggests that Alzheimer’s disease damages the brain in two separate phases, with the first phase happening ...

Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing ...

A groundbreaking study reveals how a rare combination of genetics, proteomics, and environmental factors may hold the key to delaying or preventing Alzheimer's, challenging long-held assumptions about ...

Researchers have identified a unique mitochondrial process in CA2 neurons that supports learning, memory, and social ...

A complementary drug to combat Alzheimer’s disease could target a specific part of the nerve cell protein tau.

Researchers say CSF biomarker test correlates with the severity of cognitive decline, independent of other factors, including brain amyloid deposition.

Drugs targeting amyloid plaques have failed to show efficacy in clinical trials. A new approach is needed to tackle AD ...

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the ...

Whether they can also meaningfully act on regions involved in ... buildup of the protein tau in the brain, which is a key contributor to Alzheimer’s disease. Scaling back tau buildup could ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test can detect small amounts of the clumping-prone tau protein and its misfolded pathological forms ...